PCVX Vaxcyte, Inc. Insider Trading

CEO Grant Pickering sells 24,461 shares ($1.3M) via scheduled 10b5-1 plan; retains 135,215 shares post-transaction

Grant Pickering, CHIEF EXECUTIVE OFFICER, executed 4 separate sales totaling 24,461 shares (24.5K shares) for $1,284,204.75 ($1.3M) at a blended average price of $52.50 under a pre-arranged 10b5-1 trading plan adopted on 2026-03-03. This scheduled disposition reduced his direct holdings by -15.3% from 159,676 shares to 135,215 shares post-transaction. The sale occurs in an unprofitable company context—net income was $-320,622,000.00 ($-320.6M) over the most recent full fiscal year—and at a stock price -20.9% below the 52-week high of $65.00, though this scheduled trade is not itself subject to timing characterization. His prior open-market sales across all tickers show an average 90-day return of -22.7%, while same-ticker history at PCVX shows five prior sells with 90-day returns ranging from -13.5% to -22.4%, providing context for the broader pattern of sell activity by this insider.

PCVX CFO Guggenhime sells 10,000 shares ($530.0K) under scheduled 10b5-1 plan; retains 104.4K shares plus 236,827 stock options

Andrew Guggenhime, PRESIDENT AND CFO, sold 10,000 shares of Vaxcyte (PCVX) at $53.00 on 2026-06-18 as part of a pre-arranged 10b5-1 trading plan adopted on 2026-03-04—a scheduled, non-discretionary transaction. This sale reduces his non-derivative holdings from 114.4K shares to 104.4K shares (-8.7%), but he retains substantial equity exposure through 236,827 stock options. His prior sales at PCVX show consistent weakness in subsequent performance: five prior sells between January–February 2025 recorded 30-day declines ranging from -4.2% to -12.0% and 90-day declines from -61.7% to -65.4%. The current stock price of $51.44 is -20.9% from its 52-week high of $65.00, and the company remains unprofitable with net income of -$320.6M. The scheduled nature of this trade removes discretionary timing as a signal, but the historical pattern of negative returns following his prior PCVX sales underscores elevated volatility and fundamental weakness in the stock's recent trajectory.

COO Wassil Jim sold 8,000 shares at blended $73.27, stock down 38.9% from 52-week high; company unprofitable with -$103.1M net income.

Wassil Jim, Chief Operating Officer of Vaxcyte, Inc., executed two separate sales on 2025-03-03 totaling 8,000 shares for $586,165.12 at prices of $73.07 and $73.84, reducing his holdings by 5.0% to 151,916 shares. The transaction occurs as the stock trades 38.9% below its 52-week high of $117.93, with a sharp 18.4% decline over the prior 30 days and 20.2% decline over 90 days. The company is fundamentally challenged: it reported a net loss of $103,124,000 for its most recent full fiscal year, indicating ongoing operational headwinds. His cross-ticker track record shows a 100% well-timed rate on prior sells, though his same-ticker history at PCVX remains incomplete due to recent February and January trades with outcomes still pending measurement. The confluence of significant stock weakness, unprofitable operations, and substantial share reduction by a senior executive deserves investor attention.

CFO Andrew Guggenhime sold 8,000 shares at $83.85 avg, reducing stake 6.8%; stock down 29.3% from 52-week high.

Andrew Guggenhime, President and CFO, executed 2 separate sales totaling 8,000 shares for $670,822.74 on 2025-02-18, reducing his holdings from 117,491 to 109,491 shares. The sales occurred at a blended average price of $83.85, while the stock currently trades at $83.36, near recent lows and 29.3% below its 52-week high of $117.93. Vaxcyte remains unprofitable with a net loss of $103,124,000.00 over its most recent full fiscal year. While Guggenhime's cross-ticker track record shows a 90-day well-timed selling rate of 61.54%, his prior sales at PCVX specifically have not yet demonstrated measurable outcomes at the 90-day mark, and his three most recent PCVX sales on 2025-01-21 lack measurable returns, limiting forward-looking inference from this particular insider's historical accuracy at this ticker.

COO Wassil Jim sold 8,000 shares of PCVX for $689.8K on 2025-02-03; post-transaction holds 205.7K shares

Wassil Jim, the Chief Operating Officer, executed three separate sales totaling 8,000 shares for $689,790.43 at an average price of $86.22 on 2025-02-03. This represents a -3.7% reduction in his holdings, leaving him with 205,695 shares. The timing of this sale is notable: the stock is currently -26.6% from its 52-week high of $117.93, suggesting the executive sold near elevated valuations despite the company's unprofitable state (net income of $-103.1M). His cross-ticker track record shows 20 prior sells with a 100.00% well-timed rate at the 90-day mark, though his same-ticker history at PCVX reveals mixed recent performance with his prior five sales at this ticker showing 0 of 0 well-timed outcomes measurable at 90 days. The magnitude and execution across three tranches suggests a deliberate approach, warranting observation of whether this signals executive positioning in a currently loss-making operation.

PCVX CFO sells 8,000 shares for $692,100.56; fifth sale in 34 days as stock falls -22.9% in 90 days.

Andrew Guggenhime (President and CFO) executed 3 separate sales totaling 8,000 shares for $692,100.56 on 2025-01-21, reducing holdings from 117,491 to 109,491 shares. This is the fifth discrete transaction in January and December 2024—prior same-ticker sales on 2024-12-18 and 2024-11-18 followed a similar pattern. The stock has declined -22.9% over 90 days and is trading -26.5% below its 52-week high of $117.93. While his cross-ticker track record shows a 90-day well-timed rate of 38.46% across 20 prior sales, his PCVX-specific prior trades show adverse outcomes: all four measurable prior sales at this ticker posted negative 30-day returns (ranging from -0.8% to -5.5%). The company is unprofitable with a net loss of $103,124,000.00 in the most recent full fiscal year. The repeated execution of multiple daily sales over consecutive weeks, combined with the persistent post-sale negative returns at this ticker, warrants investor attention to whether near-term business or valuation developments are driving the liquidation activity.

COO Wassil Jim sold 8,000 shares across 3 transactions for $669,266.90 at $83.66 blended average on 2025-01-02.

Wassil Jim, the Chief Operating Officer of Vaxcyte, Inc., executed three separate sales totaling 8,000 shares (8.0K shares) for $669,266.90, reducing his holdings by 3.7% to 205,695 shares (205.7K shares). The sales occurred at prices ranging from $82.88 to $84.43, near the current price of $84.86, yet the stock has declined 8.8% over the prior 30 days and 23.8% over 90 days. Notably, across his prior five trades at PCVX, all five were sells executed in November and December 2024, each followed by declines ranging from 11.1% to 13.4% over the 30-day period, suggesting a consistent pattern of selling into downward price movement rather than ahead of broader deterioration. The company remains unprofitable with net income of $-103,124,000.00 over its most recent full fiscal year, providing fundamental context to sustained insider sales activity.

PCVX President/CFO Guggenhime sells 8,000 shares for $710,248.57 on 2024-12-18; stock down 26.9% from 52-week high.

Guggenhime executed 4 separate sales totaling 8,000 shares for $710,248.57 at blended average price $88.78, reducing his holdings by 6.8% from 117.5K to 109.5K shares. The timing is notable relative to the stock's 52-week trajectory: he sold at $86.21–$90.24 while the stock currently trades at $86.21, down 26.9% from its $117.93 high and 25.2% lower over the prior 90 days. His cross-ticker track record shows a 90-day well-timed rate of 20.00% across 20 prior sells, but at PCVX specifically, none of his 5 prior measurable trades have generated positive 90-day returns—the most recent sales on 2024-10-18 saw 30-day declines of -24.7% and -25.3%. The company reported a -$103.1M net loss over its most recent full fiscal year, providing fundamental context for the stock's weakness. This sale occurs as the stock approaches its recent lows, though whether this represents prescient positioning or reactive selling is not determinable from price action alone.

CEO Pickering Grant sold 15,000 PCVX shares for $1.4M blended at $92.45; stock down 15.8% in 30 days, 23.4% from 52-week high.

Pickering Grant, CEO of Vaxcyte, Inc., executed 3 separate sales totaling 15,000 shares for $1,386,794.41 on 2024-12-02, reducing his holdings by 3.2% to 450,301 shares. The company is unprofitable (net income $-103,124,000.00) and the stock has declined 15.8% over 30 days and 23.4% from its 52-week high of $117.93, now at $90.37. His prior sales at PCVX show negative 30-day returns (-13.0%, -11.3%, -12.1%, -4.3%, -5.0%), establishing a pattern of sales preceding near-term weakness, though 90-day outcomes remain unmeasurable for recent trades. The CEO's cross-ticker track record shows an average 30-day return of -6.7% following 20 prior sells, and combined with current price weakness, this sale occurs within a period of sustained stock pressure.

Wassil Jim (COO) sells 8,000 shares for $739,884.53 at blended avg $92.49 amid stock down -23.4% from 52-week high.

Wassil Jim, Chief Operating Officer of Vaxcyte, executed 3 separate sales totaling 8,000 shares for $739,884.53 on 2024-12-02, reducing his holdings from 213.7K to 205.7K shares (-3.7%). The sales occurred at prices ranging from $92.07 to $94.06 per share, while the stock currently trades at $90.37—below all transaction prices and down -23.4% from its 52-week high of $117.93. The company reported a net loss of $-103.1M in its most recent full fiscal year. Jim's prior PCVX sales (5 trades over the past two months in October and November) showed consistent post-sale declines of -7.0% to -13.4% over 30-day periods, suggesting his recent sales have coincided with sustained downward pressure. No measurable 90-day outcomes are yet available on those prior trades to assess longer-term timing accuracy at this ticker.